Placebo (oral)
Sponsors
Eli Lilly and Company, Janssen Research & Development, LLC, Applied Molecular Transport, Johns Hopkins University, Walter Reed Army Institute of Research (WRAIR)
Conditions
Acute Stress ReactionBinge Eating DisorderDepressive Disorder, MajorDiabetes Mellitus, Type 2Fear of SpidersObesity and OverweightType 2 Diabetes Mellitus (T2DM)Ulcerative Colitis
Phase 1
Phase 2
Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)
NCT04583358
Start: 2020-08-26End: 2022-12-31Updated: 2022-11-07
Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)
CompletedNCT05372939
Start: 2021-02-05End: 2022-07-13Updated: 2022-09-14
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
RecruitingNCT06847399
Start: 2025-09-17End: 2027-12-01Target: 105Updated: 2025-09-22